Cytokinetics, Incorporated (CYTK) Stock Competitors & Peer Comparison
See (CYTK) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CYTK | $71.13 | -7.33% | 9.2B | -10.76 | -$6.85 | N/A |
| NVO | $42.99 | -5.69% | 195.8B | 10.34 | $4.26 | +4.05% |
| VRTX | $427.64 | -4.45% | 111.3B | 25.99 | $16.87 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $602.20 | -2.05% | 61.9B | 14.67 | $40.94 | +0.60% |
| ARGX | $804.08 | -3.82% | 51.7B | 37.08 | $22.55 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $288.26 | -4.55% | 39.5B | 74.09 | $3.99 | N/A |
| RVMD | $151.65 | -3.70% | 34.8B | -23.02 | -$7.11 | N/A |
| RPRX | $54.18 | -2.84% | 23.7B | 29.04 | $1.90 | +1.66% |
Stock Comparison
CYTK vs NVO Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, NVO has a market cap of 195.8B. Regarding current trading prices, CYTK is priced at $71.13, while NVO trades at $42.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas NVO's P/E ratio is 10.34. In terms of profitability, CYTK's ROE is +1.40%, compared to NVO's ROE of +0.66%. Regarding short-term risk, CYTK is more volatile compared to NVO. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check NVO's competition here
CYTK vs VRTX Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, VRTX has a market cap of 111.3B. Regarding current trading prices, CYTK is priced at $71.13, while VRTX trades at $427.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas VRTX's P/E ratio is 25.99. In terms of profitability, CYTK's ROE is +1.40%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, CYTK is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check VRTX's competition here
CYTK vs VRNA Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, CYTK is priced at $71.13, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas VRNA's P/E ratio is -102.80. In terms of profitability, CYTK's ROE is +1.40%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, CYTK is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check VRNA's competition here
CYTK vs REGN Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, REGN has a market cap of 61.9B. Regarding current trading prices, CYTK is priced at $71.13, while REGN trades at $602.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas REGN's P/E ratio is 14.67. In terms of profitability, CYTK's ROE is +1.40%, compared to REGN's ROE of +0.14%. Regarding short-term risk, CYTK is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check REGN's competition here
CYTK vs ARGX Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, ARGX has a market cap of 51.7B. Regarding current trading prices, CYTK is priced at $71.13, while ARGX trades at $804.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas ARGX's P/E ratio is 37.08. In terms of profitability, CYTK's ROE is +1.40%, compared to ARGX's ROE of +0.37%. Regarding short-term risk, CYTK is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check ARGX's competition here
CYTK vs SGEN Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, CYTK is priced at $71.13, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas SGEN's P/E ratio is -57.19. In terms of profitability, CYTK's ROE is +1.40%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, CYTK is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check SGEN's competition here
CYTK vs ALNY Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, ALNY has a market cap of 39.5B. Regarding current trading prices, CYTK is priced at $71.13, while ALNY trades at $288.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas ALNY's P/E ratio is 74.09. In terms of profitability, CYTK's ROE is +1.40%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, CYTK is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check ALNY's competition here
CYTK vs RVMD Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, RVMD has a market cap of 34.8B. Regarding current trading prices, CYTK is priced at $71.13, while RVMD trades at $151.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas RVMD's P/E ratio is -23.02. In terms of profitability, CYTK's ROE is +1.40%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, CYTK is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for CYTK.Check RVMD's competition here
CYTK vs RPRX Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, RPRX has a market cap of 23.7B. Regarding current trading prices, CYTK is priced at $71.13, while RPRX trades at $54.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas RPRX's P/E ratio is 29.04. In terms of profitability, CYTK's ROE is +1.40%, compared to RPRX's ROE of +0.13%. Regarding short-term risk, CYTK is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check RPRX's competition here
CYTK vs BNTX Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, BNTX has a market cap of 23.2B. Regarding current trading prices, CYTK is priced at $71.13, while BNTX trades at $88.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas BNTX's P/E ratio is -15.57. In terms of profitability, CYTK's ROE is +1.40%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, CYTK is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check BNTX's competition here
CYTK vs UTHR Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, UTHR has a market cap of 23.1B. Regarding current trading prices, CYTK is priced at $71.13, while UTHR trades at $537.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas UTHR's P/E ratio is 20.13. In terms of profitability, CYTK's ROE is +1.40%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, CYTK is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check UTHR's competition here
CYTK vs INSM Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, INSM has a market cap of 23B. Regarding current trading prices, CYTK is priced at $71.13, while INSM trades at $103.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas INSM's P/E ratio is -18.41. In terms of profitability, CYTK's ROE is +1.40%, compared to INSM's ROE of -1.30%. Regarding short-term risk, CYTK is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check INSM's competition here
CYTK vs ROIV Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, ROIV has a market cap of 20.9B. Regarding current trading prices, CYTK is priced at $71.13, while ROIV trades at $28.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas ROIV's P/E ratio is -53.87. In terms of profitability, CYTK's ROE is +1.40%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, CYTK is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check ROIV's competition here
CYTK vs BGNE Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, CYTK is priced at $71.13, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas BGNE's P/E ratio is -22.55. In terms of profitability, CYTK's ROE is +1.40%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, CYTK is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check BGNE's competition here
CYTK vs INCY Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, INCY has a market cap of 19.1B. Regarding current trading prices, CYTK is priced at $71.13, while INCY trades at $93.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas INCY's P/E ratio is 13.50. In terms of profitability, CYTK's ROE is +1.40%, compared to INCY's ROE of +0.29%. Regarding short-term risk, CYTK is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check INCY's competition here
CYTK vs DNA-WT Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, CYTK is priced at $71.13, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, CYTK's ROE is +1.40%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, CYTK is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for CYTK.Check DNA-WT's competition here
CYTK vs MRNA Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, MRNA has a market cap of 18.3B. Regarding current trading prices, CYTK is priced at $71.13, while MRNA trades at $45.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas MRNA's P/E ratio is -5.66. In terms of profitability, CYTK's ROE is +1.40%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, CYTK is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check MRNA's competition here
CYTK vs NBIX Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, NBIX has a market cap of 16.2B. Regarding current trading prices, CYTK is priced at $71.13, while NBIX trades at $155.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas NBIX's P/E ratio is 24.73. In terms of profitability, CYTK's ROE is +1.40%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, CYTK is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check NBIX's competition here
CYTK vs GMAB Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, GMAB has a market cap of 15.6B. Regarding current trading prices, CYTK is priced at $71.13, while GMAB trades at $24.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas GMAB's P/E ratio is 19.43. In terms of profitability, CYTK's ROE is +1.40%, compared to GMAB's ROE of +0.21%. Regarding short-term risk, CYTK is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check GMAB's competition here
CYTK vs JAZZ Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, JAZZ has a market cap of 14.6B. Regarding current trading prices, CYTK is priced at $71.13, while JAZZ trades at $226.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas JAZZ's P/E ratio is 1938.67. In terms of profitability, CYTK's ROE is +1.40%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, CYTK is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check JAZZ's competition here
CYTK vs ASND Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, ASND has a market cap of 13.5B. Regarding current trading prices, CYTK is priced at $71.13, while ASND trades at $217.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas ASND's P/E ratio is 24.87. In terms of profitability, CYTK's ROE is +1.40%, compared to ASND's ROE of -56.42%. Regarding short-term risk, CYTK is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check ASND's competition here
CYTK vs BBIO Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, BBIO has a market cap of 12.8B. Regarding current trading prices, CYTK is priced at $71.13, while BBIO trades at $63.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas BBIO's P/E ratio is -17.48. In terms of profitability, CYTK's ROE is +1.40%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, CYTK is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check BBIO's competition here
CYTK vs EXEL Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, EXEL has a market cap of 12.6B. Regarding current trading prices, CYTK is priced at $71.13, while EXEL trades at $48.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas EXEL's P/E ratio is 16.65. In terms of profitability, CYTK's ROE is +1.40%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, CYTK is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check EXEL's competition here
CYTK vs KRTX Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, CYTK is priced at $71.13, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas KRTX's P/E ratio is -28.09. In terms of profitability, CYTK's ROE is +1.40%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, CYTK is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check KRTX's competition here
CYTK vs IONS Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, IONS has a market cap of 12.5B. Regarding current trading prices, CYTK is priced at $71.13, while IONS trades at $73.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas IONS's P/E ratio is -37.50. In terms of profitability, CYTK's ROE is +1.40%, compared to IONS's ROE of -0.59%. Regarding short-term risk, CYTK is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check IONS's competition here
CYTK vs SMMT Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, SMMT has a market cap of 12.2B. Regarding current trading prices, CYTK is priced at $71.13, while SMMT trades at $14.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas SMMT's P/E ratio is -9.88. In terms of profitability, CYTK's ROE is +1.40%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, CYTK is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for CYTK.Check SMMT's competition here
CYTK vs AXSM Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, AXSM has a market cap of 11.8B. Regarding current trading prices, CYTK is priced at $71.13, while AXSM trades at $221.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas AXSM's P/E ratio is -62.06. In terms of profitability, CYTK's ROE is +1.40%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, CYTK is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check AXSM's competition here
CYTK vs RNAM Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, CYTK is priced at $71.13, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas RNAM's P/E ratio is -17.39. In terms of profitability, CYTK's ROE is +1.40%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, CYTK is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check RNAM's competition here
CYTK vs MDGL Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, MDGL has a market cap of 11.1B. Regarding current trading prices, CYTK is priced at $71.13, while MDGL trades at $459.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas MDGL's P/E ratio is -35.70. In terms of profitability, CYTK's ROE is +1.40%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, CYTK is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check MDGL's competition here
CYTK vs BMRN Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, BMRN has a market cap of 10.6B. Regarding current trading prices, CYTK is priced at $71.13, while BMRN trades at $54.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas BMRN's P/E ratio is 39.59. In terms of profitability, CYTK's ROE is +1.40%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, CYTK is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check BMRN's competition here
CYTK vs ARWR Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, ARWR has a market cap of 10.6B. Regarding current trading prices, CYTK is priced at $71.13, while ARWR trades at $71.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas ARWR's P/E ratio is -33.13. In terms of profitability, CYTK's ROE is +1.40%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, CYTK is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for CYTK.Check ARWR's competition here
CYTK vs RXDX Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, CYTK is priced at $71.13, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas RXDX's P/E ratio is -56.47. In terms of profitability, CYTK's ROE is +1.40%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, CYTK is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check RXDX's competition here
CYTK vs KRYS Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, KRYS has a market cap of 8.8B. Regarding current trading prices, CYTK is priced at $71.13, while KRYS trades at $294.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas KRYS's P/E ratio is 39.96. In terms of profitability, CYTK's ROE is +1.40%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, CYTK is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check KRYS's competition here
CYTK vs IMGN Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, CYTK is priced at $71.13, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas IMGN's P/E ratio is -111.55. In terms of profitability, CYTK's ROE is +1.40%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, CYTK is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check IMGN's competition here
CYTK vs ABVX Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, ABVX has a market cap of 8.5B. Regarding current trading prices, CYTK is priced at $71.13, while ABVX trades at $73.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas ABVX's P/E ratio is -24.20. In terms of profitability, CYTK's ROE is +1.40%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, CYTK is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for CYTK.Check ABVX's competition here
CYTK vs BPMC Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, CYTK is priced at $71.13, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas BPMC's P/E ratio is -51.58. In terms of profitability, CYTK's ROE is +1.40%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, CYTK is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check BPMC's competition here
CYTK vs CERE Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, CYTK is priced at $71.13, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas CERE's P/E ratio is -16.47. In terms of profitability, CYTK's ROE is +1.40%, compared to CERE's ROE of -0.72%. Regarding short-term risk, CYTK is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check CERE's competition here
CYTK vs HALO Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, HALO has a market cap of 8.1B. Regarding current trading prices, CYTK is priced at $71.13, while HALO trades at $66.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas HALO's P/E ratio is 23.91. In terms of profitability, CYTK's ROE is +1.40%, compared to HALO's ROE of +1.26%. Regarding short-term risk, CYTK is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check HALO's competition here
CYTK vs TECH Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, TECH has a market cap of 8B. Regarding current trading prices, CYTK is priced at $71.13, while TECH trades at $49.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas TECH's P/E ratio is 72.56. In terms of profitability, CYTK's ROE is +1.40%, compared to TECH's ROE of +0.05%. Regarding short-term risk, CYTK is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check TECH's competition here
CYTK vs IBRX Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, IBRX has a market cap of 7.6B. Regarding current trading prices, CYTK is priced at $71.13, while IBRX trades at $7.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas IBRX's P/E ratio is -8.52. In terms of profitability, CYTK's ROE is +1.40%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, CYTK is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check IBRX's competition here
CYTK vs CORT Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, CORT has a market cap of 7.6B. Regarding current trading prices, CYTK is priced at $71.13, while CORT trades at $70.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas CORT's P/E ratio is 201.26. In terms of profitability, CYTK's ROE is +1.40%, compared to CORT's ROE of +0.08%. Regarding short-term risk, CYTK is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check CORT's competition here
CYTK vs MTSR Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, CYTK is priced at $71.13, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas MTSR's P/E ratio is -23.58. In terms of profitability, CYTK's ROE is +1.40%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, CYTK is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check MTSR's competition here
CYTK vs PRAX Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, PRAX has a market cap of 7.1B. Regarding current trading prices, CYTK is priced at $71.13, while PRAX trades at $272.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas PRAX's P/E ratio is -25.01. In terms of profitability, CYTK's ROE is +1.40%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, CYTK is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for CYTK.Check PRAX's competition here
CYTK vs PCVX Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, PCVX has a market cap of 7.1B. Regarding current trading prices, CYTK is priced at $71.13, while PCVX trades at $47.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas PCVX's P/E ratio is -7.10. In terms of profitability, CYTK's ROE is +1.40%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, CYTK is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check PCVX's competition here
CYTK vs ALKS Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, ALKS has a market cap of 7B. Regarding current trading prices, CYTK is priced at $71.13, while ALKS trades at $41.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas ALKS's P/E ratio is 46.97. In terms of profitability, CYTK's ROE is +1.40%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, CYTK is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check ALKS's competition here
CYTK vs NUVL Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, NUVL has a market cap of 6.8B. Regarding current trading prices, CYTK is priced at $71.13, while NUVL trades at $91.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas NUVL's P/E ratio is -15.35. In terms of profitability, CYTK's ROE is +1.40%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, CYTK is less volatile compared to NUVL. This indicates potentially lower risk in terms of short-term price fluctuations for CYTK.Check NUVL's competition here
CYTK vs MRUS Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, CYTK is priced at $71.13, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas MRUS's P/E ratio is -17.05. In terms of profitability, CYTK's ROE is +1.40%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, CYTK is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check MRUS's competition here
CYTK vs IMVT Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, IMVT has a market cap of 6.7B. Regarding current trading prices, CYTK is priced at $71.13, while IMVT trades at $30.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas IMVT's P/E ratio is -11.86. In terms of profitability, CYTK's ROE is +1.40%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, CYTK is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for CYTK.Check IMVT's competition here
CYTK vs ACLX Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, CYTK is priced at $71.13, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas ACLX's P/E ratio is -28.27. In terms of profitability, CYTK's ROE is +1.40%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, CYTK is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check ACLX's competition here
CYTK vs RETA Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, CYTK is priced at $71.13, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas RETA's P/E ratio is -66.29. In terms of profitability, CYTK's ROE is +1.40%, compared to RETA's ROE of +0.47%. Regarding short-term risk, CYTK is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check RETA's competition here
CYTK vs KYMR Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, KYMR has a market cap of 6.5B. Regarding current trading prices, CYTK is priced at $71.13, while KYMR trades at $72.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas KYMR's P/E ratio is -21.92. In terms of profitability, CYTK's ROE is +1.40%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, CYTK is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for CYTK.Check KYMR's competition here
CYTK vs CNTA Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, CNTA has a market cap of 6.2B. Regarding current trading prices, CYTK is priced at $71.13, while CNTA trades at $39.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas CNTA's P/E ratio is -22.39. In terms of profitability, CYTK's ROE is +1.40%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, CYTK is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check CNTA's competition here
CYTK vs PTCT Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, PTCT has a market cap of 6.1B. Regarding current trading prices, CYTK is priced at $71.13, while PTCT trades at $68.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas PTCT's P/E ratio is -29.06. In terms of profitability, CYTK's ROE is +1.40%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, CYTK is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for CYTK.Check PTCT's competition here
CYTK vs PTGX Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, PTGX has a market cap of 6.1B. Regarding current trading prices, CYTK is priced at $71.13, while PTGX trades at $93.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas PTGX's P/E ratio is -52.35. In terms of profitability, CYTK's ROE is +1.40%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, CYTK is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check PTGX's competition here
CYTK vs RYTM Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, RYTM has a market cap of 6B. Regarding current trading prices, CYTK is priced at $71.13, while RYTM trades at $84.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas RYTM's P/E ratio is -28.07. In terms of profitability, CYTK's ROE is +1.40%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, CYTK is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check RYTM's competition here
CYTK vs CELC Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, CELC has a market cap of 6B. Regarding current trading prices, CYTK is priced at $71.13, while CELC trades at $89.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas CELC's P/E ratio is -31.53. In terms of profitability, CYTK's ROE is +1.40%, compared to CELC's ROE of -2.45%. Regarding short-term risk, CYTK is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for CYTK.Check CELC's competition here
CYTK vs COGT Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, COGT has a market cap of 5.9B. Regarding current trading prices, CYTK is priced at $71.13, while COGT trades at $33.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas COGT's P/E ratio is -16.04. In terms of profitability, CYTK's ROE is +1.40%, compared to COGT's ROE of -0.83%. Regarding short-term risk, CYTK is less volatile compared to COGT. This indicates potentially lower risk in terms of short-term price fluctuations for CYTK.Check COGT's competition here
CYTK vs BLTE Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, BLTE has a market cap of 5.9B. Regarding current trading prices, CYTK is priced at $71.13, while BLTE trades at $136.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas BLTE's P/E ratio is -57.65. In terms of profitability, CYTK's ROE is +1.40%, compared to BLTE's ROE of -0.27%. Regarding short-term risk, CYTK is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for CYTK.Check BLTE's competition here
CYTK vs TGTX Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, TGTX has a market cap of 5.7B. Regarding current trading prices, CYTK is priced at $71.13, while TGTX trades at $36.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas TGTX's P/E ratio is 13.08. In terms of profitability, CYTK's ROE is +1.40%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, CYTK is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check TGTX's competition here
CYTK vs SRRK Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, CYTK is priced at $71.13, while SRRK trades at $45.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas SRRK's P/E ratio is -13.74. In terms of profitability, CYTK's ROE is +1.40%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, CYTK is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check SRRK's competition here
CYTK vs CDTX Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, CYTK is priced at $71.13, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas CDTX's P/E ratio is -19.77. In terms of profitability, CYTK's ROE is +1.40%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, CYTK is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check CDTX's competition here
CYTK vs ABCM Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, CYTK is priced at $71.13, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, CYTK's ROE is +1.40%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, CYTK is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check ABCM's competition here
CYTK vs ISEE Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, CYTK is priced at $71.13, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas ISEE's P/E ratio is -22.44. In terms of profitability, CYTK's ROE is +1.40%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, CYTK is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check ISEE's competition here
CYTK vs APLS Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, CYTK is priced at $71.13, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas APLS's P/E ratio is 38.35. In terms of profitability, CYTK's ROE is +1.40%, compared to APLS's ROE of +0.40%. Regarding short-term risk, CYTK is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check APLS's competition here
CYTK vs CRSP Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, CRSP has a market cap of 5.2B. Regarding current trading prices, CYTK is priced at $71.13, while CRSP trades at $52.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas CRSP's P/E ratio is -8.78. In terms of profitability, CYTK's ROE is +1.40%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, CYTK is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check CRSP's competition here
CYTK vs CGON Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, CGON has a market cap of 5.2B. Regarding current trading prices, CYTK is priced at $71.13, while CGON trades at $56.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas CGON's P/E ratio is -25.31. In terms of profitability, CYTK's ROE is +1.40%, compared to CGON's ROE of -0.23%. Regarding short-term risk, CYTK is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for CYTK.Check CGON's competition here
CYTK vs LQDA Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, LQDA has a market cap of 5.2B. Regarding current trading prices, CYTK is priced at $71.13, while LQDA trades at $55.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas LQDA's P/E ratio is 345.56. In terms of profitability, CYTK's ROE is +1.40%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, CYTK is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for CYTK.Check LQDA's competition here
CYTK vs FBIOX Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, FBIOX has a market cap of 5.2B. Regarding current trading prices, CYTK is priced at $71.13, while FBIOX trades at $25.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas FBIOX's P/E ratio is N/A. In terms of profitability, CYTK's ROE is +1.40%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, CYTK is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check FBIOX's competition here
CYTK vs APGE Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, APGE has a market cap of 4.9B. Regarding current trading prices, CYTK is priced at $71.13, while APGE trades at $79.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas APGE's P/E ratio is -18.31. In terms of profitability, CYTK's ROE is +1.40%, compared to APGE's ROE of -0.33%. Regarding short-term risk, CYTK is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check APGE's competition here
CYTK vs MIRM Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, MIRM has a market cap of 4.8B. Regarding current trading prices, CYTK is priced at $71.13, while MIRM trades at $93.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas MIRM's P/E ratio is -7.08. In terms of profitability, CYTK's ROE is +1.40%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, CYTK is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for CYTK.Check MIRM's competition here
CYTK vs TERN Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, CYTK is priced at $71.13, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas TERN's P/E ratio is -51.41. In terms of profitability, CYTK's ROE is +1.40%, compared to TERN's ROE of -0.20%. Regarding short-term risk, CYTK is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check TERN's competition here
CYTK vs LEGN Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, LEGN has a market cap of 4.7B. Regarding current trading prices, CYTK is priced at $71.13, while LEGN trades at $36.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas LEGN's P/E ratio is -18.49. In terms of profitability, CYTK's ROE is +1.40%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, CYTK is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for CYTK.Check LEGN's competition here
CYTK vs CAI Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, CAI has a market cap of 4.7B. Regarding current trading prices, CYTK is priced at $71.13, while CAI trades at $16.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas CAI's P/E ratio is -5.96. In terms of profitability, CYTK's ROE is +1.40%, compared to CAI's ROE of +0.06%. Regarding short-term risk, CYTK is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for CYTK.Check CAI's competition here
CYTK vs LGND Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, LGND has a market cap of 4.6B. Regarding current trading prices, CYTK is priced at $71.13, while LGND trades at $232.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas LGND's P/E ratio is 29.92. In terms of profitability, CYTK's ROE is +1.40%, compared to LGND's ROE of +0.16%. Regarding short-term risk, CYTK is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check LGND's competition here
CYTK vs FOLD Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, CYTK is priced at $71.13, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas FOLD's P/E ratio is -161.00. In terms of profitability, CYTK's ROE is +1.40%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, CYTK is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check FOLD's competition here
CYTK vs AKRO Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, CYTK is priced at $71.13, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas AKRO's P/E ratio is -14.57. In terms of profitability, CYTK's ROE is +1.40%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, CYTK is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check AKRO's competition here
CYTK vs ALPN Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, CYTK is priced at $71.13, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas ALPN's P/E ratio is -101.52. In terms of profitability, CYTK's ROE is +1.40%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, CYTK is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check ALPN's competition here
CYTK vs EWTX Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, EWTX has a market cap of 4.3B. Regarding current trading prices, CYTK is priced at $71.13, while EWTX trades at $37.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas EWTX's P/E ratio is -24.25. In terms of profitability, CYTK's ROE is +1.40%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, CYTK is less volatile compared to EWTX. This indicates potentially lower risk in terms of short-term price fluctuations for CYTK.Check EWTX's competition here
CYTK vs ERAS Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, ERAS has a market cap of 4.3B. Regarding current trading prices, CYTK is priced at $71.13, while ERAS trades at $13.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas ERAS's P/E ratio is -14.86. In terms of profitability, CYTK's ROE is +1.40%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, CYTK is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for CYTK.Check ERAS's competition here
CYTK vs SYRE Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, SYRE has a market cap of 4.3B. Regarding current trading prices, CYTK is priced at $71.13, while SYRE trades at $68.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas SYRE's P/E ratio is -33.27. In terms of profitability, CYTK's ROE is +1.40%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, CYTK is more volatile compared to SYRE. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check SYRE's competition here
CYTK vs MANE Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, MANE has a market cap of 4.2B. Regarding current trading prices, CYTK is priced at $71.13, while MANE trades at $98.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas MANE's P/E ratio is -38.50. In terms of profitability, CYTK's ROE is +1.40%, compared to MANE's ROE of -0.95%. Regarding short-term risk, CYTK is less volatile compared to MANE. This indicates potentially lower risk in terms of short-term price fluctuations for CYTK.Check MANE's competition here
CYTK vs OPT Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, CYTK is priced at $71.13, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas OPT's P/E ratio is -1.52. In terms of profitability, CYTK's ROE is +1.40%, compared to OPT's ROE of +0.88%. Regarding short-term risk, CYTK is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check OPT's competition here
CYTK vs XENE Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, XENE has a market cap of 4.2B. Regarding current trading prices, CYTK is priced at $71.13, while XENE trades at $52.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas XENE's P/E ratio is -11.36. In terms of profitability, CYTK's ROE is +1.40%, compared to XENE's ROE of -0.49%. Regarding short-term risk, CYTK is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check XENE's competition here
CYTK vs TVTX Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, TVTX has a market cap of 4.2B. Regarding current trading prices, CYTK is priced at $71.13, while TVTX trades at $42.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas TVTX's P/E ratio is -90.08. In terms of profitability, CYTK's ROE is +1.40%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, CYTK is less volatile compared to TVTX. This indicates potentially lower risk in terms of short-term price fluctuations for CYTK.Check TVTX's competition here
CYTK vs MRTX Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, CYTK is priced at $71.13, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas MRTX's P/E ratio is -4.82. In terms of profitability, CYTK's ROE is +1.40%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, CYTK is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check MRTX's competition here
CYTK vs VCYT Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, VCYT has a market cap of 3.8B. Regarding current trading prices, CYTK is priced at $71.13, while VCYT trades at $47.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas VCYT's P/E ratio is 44.61. In terms of profitability, CYTK's ROE is +1.40%, compared to VCYT's ROE of +0.07%. Regarding short-term risk, CYTK is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check VCYT's competition here
CYTK vs CPRX Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, CPRX has a market cap of 3.8B. Regarding current trading prices, CYTK is priced at $71.13, while CPRX trades at $31.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas CPRX's P/E ratio is 18.08. In terms of profitability, CYTK's ROE is +1.40%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, CYTK is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check CPRX's competition here
CYTK vs RYZB Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, CYTK is priced at $71.13, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas RYZB's P/E ratio is -57.86. In terms of profitability, CYTK's ROE is +1.40%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, CYTK is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check RYZB's competition here
CYTK vs DNTH Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, DNTH has a market cap of 3.7B. Regarding current trading prices, CYTK is priced at $71.13, while DNTH trades at $83.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas DNTH's P/E ratio is -21.15. In terms of profitability, CYTK's ROE is +1.40%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, CYTK is less volatile compared to DNTH. This indicates potentially lower risk in terms of short-term price fluctuations for CYTK.Check DNTH's competition here
CYTK vs CBAY Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, CYTK is priced at $71.13, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas CBAY's P/E ratio is -32.81. In terms of profitability, CYTK's ROE is +1.40%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, CYTK is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check CBAY's competition here
CYTK vs NAMS Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, NAMS has a market cap of 3.7B. Regarding current trading prices, CYTK is priced at $71.13, while NAMS trades at $31.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas NAMS's P/E ratio is -17.86. In terms of profitability, CYTK's ROE is +1.40%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, CYTK is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check NAMS's competition here
CYTK vs ACAD Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, ACAD has a market cap of 3.7B. Regarding current trading prices, CYTK is priced at $71.13, while ACAD trades at $20.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas ACAD's P/E ratio is 9.74. In terms of profitability, CYTK's ROE is +1.40%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, CYTK is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check ACAD's competition here
CYTK vs KNSA Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, KNSA has a market cap of 3.6B. Regarding current trading prices, CYTK is priced at $71.13, while KNSA trades at $46.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas KNSA's P/E ratio is 53.22. In terms of profitability, CYTK's ROE is +1.40%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, CYTK is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check KNSA's competition here
CYTK vs CRNX Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, CRNX has a market cap of 3.6B. Regarding current trading prices, CYTK is priced at $71.13, while CRNX trades at $32.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas CRNX's P/E ratio is -6.72. In terms of profitability, CYTK's ROE is +1.40%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, CYTK is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for CYTK.Check CRNX's competition here
CYTK vs VKTX Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, VKTX has a market cap of 3.6B. Regarding current trading prices, CYTK is priced at $71.13, while VKTX trades at $29.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas VKTX's P/E ratio is -7.53. In terms of profitability, CYTK's ROE is +1.40%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, CYTK is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for CYTK.Check VKTX's competition here
CYTK vs SWTX Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, CYTK is priced at $71.13, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas SWTX's P/E ratio is -13.78. In terms of profitability, CYTK's ROE is +1.40%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, CYTK is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check SWTX's competition here
CYTK vs DNLI Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, DNLI has a market cap of 3.2B. Regarding current trading prices, CYTK is priced at $71.13, while DNLI trades at $19.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas DNLI's P/E ratio is -7.09. In terms of profitability, CYTK's ROE is +1.40%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, CYTK is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for CYTK.Check DNLI's competition here
CYTK vs BEAM Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, BEAM has a market cap of 3.2B. Regarding current trading prices, CYTK is priced at $71.13, while BEAM trades at $29.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas BEAM's P/E ratio is -63.55. In terms of profitability, CYTK's ROE is +1.40%, compared to BEAM's ROE of -0.06%. Regarding short-term risk, CYTK is less volatile compared to BEAM. This indicates potentially lower risk in terms of short-term price fluctuations for CYTK.Check BEAM's competition here
CYTK vs TLX Comparison June 2026
CYTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTK stands at 9.2B. In comparison, TLX has a market cap of 3.2B. Regarding current trading prices, CYTK is priced at $71.13, while TLX trades at $9.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTK currently has a P/E ratio of -10.76, whereas TLX's P/E ratio is -471.00. In terms of profitability, CYTK's ROE is +1.40%, compared to TLX's ROE of -0.02%. Regarding short-term risk, CYTK is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for CYTK.Check TLX's competition here